1. Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. (3rd March 2016) Authors: Usmani, S. Z.; Cavenagh, J. D.; Belch, A. R.; Hulin, C.; Basu, S.; White, D.; Nooka, A.; Ervin-Haynes, A.; Yiu, W.; Nagarwala, Y.; Berger, A.; Pelligra, C. G.; Guo, S.; Binder, G.; Gibson, C. J.; Facon, T. Journal: Journal of medical economics Issue: Volume 19:Number 3(2016) Page Start: 243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA. (23rd June 2022) Authors: Hasan Bou Issa, L.; Fléchon, L.; Laine, W.; Ouelkdite, A.; Escure, G.; Gaggero, S.; Ingegnere, T.; Sklavenitis Pistofidis, R.; Ghobrial, I. M.; Facon, T.; Mitra, S.; Kluza, J.; Quesnel, B.; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY. (23rd June 2022) Authors: Quach, H.; Leleu, X.; Mateos, M.-V.; Usmani, S. Z.; Nooka, A. K.; Goldrick, A.; Najdi, R.; Shu, N.; Facon, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 798 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. (23rd June 2022) Authors: Facon, T.; Kumar, S. K.; Plesner, T.; Moreau, P.; Bahlis, N.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Mace, J. R.; Raje, N.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Borgsten, F.; Usmani, S. Z. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 826 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY. (23rd June 2022) Authors: Nooka, A.; Lonial, S.; Grosicki, S.; Hus, M.; Song, K.; Facon, T.; Callander, N. S.; Ribrag, V.; Uttervall, K.; Quach, H.; Vorobyev, V.; Min, C.-K.; Cheng, S.; Smith, L. M.; Yu, J.; Collingwood, T.; Holkova, B.; Kremer, B. E.; Gupta, I. V.; Richardson, P. G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. POLICY, SCIENCE AND SOCIETY INTERACTION†. (18th March 2014) Authors: Tollefson, L.; El Atfy, H.; Facon, T.; Kerc, A.; Tyagi, Avinash C.; Gundogdu, Huseyin; Schultz, Bart Journal: Irrigation and drainage Issue: Volume 63:Number 2(2014:Apr.) Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. (23rd June 2022) Authors: Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL. (23rd June 2022) Authors: Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗